Katoh Toshihiko, Yamamoto Kenji
1 Graduate School of Biostudies, Kyoto University.
2 Center for Innovative and Joint Research, Wakayama University.
J Appl Glycosci (1999). 2021 Mar 11;68(1):1-9. doi: 10.5458/jag.jag.JAG-2020_0013. eCollection 2021.
Most functional biopharmaceuticals such as antibodies are glycoproteins carrying -linked oligosaccharides (-glycans). In animal cells, these glycans are generally expressed as heterogeneous glycoforms that are difficult to separate into a pure form. The structure of these glycans directly affects several biological aspects of the glycoproteins, especially binding affinity. Therefore, the preparation of glycoproteins with well-defined and homogeneous glycoforms is necessary for functional studies and improved efficacy, particularly for biopharmaceuticals. This review describes the recent remarkable progress in the development and production of biopharmaceutical glycan-modified antibodies, through the use of glycan remodeling using microbial endoglycosidases and sophisticated glycoengineering techniques utilizing microbial enzymatic reaction mechanisms.
大多数功能性生物制药,如抗体,都是携带N-连接寡糖(N-聚糖)的糖蛋白。在动物细胞中,这些聚糖通常以异质糖型表达,难以分离成纯形式。这些聚糖的结构直接影响糖蛋白的几个生物学方面,尤其是结合亲和力。因此,制备具有明确且均匀糖型的糖蛋白对于功能研究和提高疗效是必要的,特别是对于生物制药。本综述描述了通过使用微生物内切糖苷酶进行聚糖重塑以及利用微生物酶促反应机制的复杂糖工程技术,在生物制药聚糖修饰抗体的开发和生产方面取得的最新显著进展。